N/A
Average UserN/A
Average AnalystVery Bearish
Stock Target AdvisorUSD 0.00
0.00 (0.00)%
USD 6.24B
N/A
N/A
N/A
Average UserN/A
Average AnalystVery Bearish
Stock Target AdvisorUSD 6.24B
USD 0.00
Based on the Momenta Pharmaceuticals, Inc stock forecasts from 0 analysts, the average analyst target price for Momenta Pharmaceuticals, Inc is not available over the next 12 months. Momenta Pharmaceuticals, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Momenta Pharmaceuticals, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Momenta Pharmaceuticals, Inc’s stock price was USD 0.00. Momenta Pharmaceuticals, Inc’s stock price has changed by 0% over the past week, 0% over the past month and 0% over the last year.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc recept...Read More
301 Binney Street, Cambridge, MA, United States, 02142
118
December
USD
USA
1.79
N/A
0.79
N/A
5,413,387
USD 37.73
4,400,542
USD 52.38
0.98%
7.57%
103.48%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
PPD Inc | 0.00 (0.00%) | USD16.61B | 47.04 | 21.58 |
|
Viatris Inc | +0.10 (+0.82%) | USD14.42B | 18.02 | 6.97 |
|
Neurocrine Biosciences Inc | -0.71 (-0.64%) | USD10.41B | 180.48 | 98.51 |
|
Mylan N.V | 0.00 (0.00%) | USD8.59B | 30.73 | 11.86 |
|
Tilray, Inc | 0.00 (0.00%) | USD6.86B | 60.60 | 454.68 |
|
Alkermes Plc | +0.05 (+0.17%) | USD4.73B | N/A | -72.85 |
|
Intracellular Th | -0.10 (-0.21%) | USD4.45B | N/A | -14.58 |
|
Lantheus Holdings Inc | +1.14 (+1.98%) | USD3.86B | 36.91 | 16.96 |
|
Evotec SE ADR | +0.10 (+1.03%) | USD3.66B | 508.00 | -19.09 |
|
HUTCHMED DRC | +0.73 (+4.05%) | USD3.64B | 17.69 | -6.38 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
no data |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had negative total cash flow in the most recent four quarters.